Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents.

Journal of cannabis research·2026

Same author

Allosteric Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase Based on N,N'-Diphenylurea.

ChemMedChem·2025

Same author

Scaled-up non-thermal plasma-generating device Plasmatico enables effective and harmless disinfection of personal protective equipment.

Scientific reports·2025

Same author

UBE2O, a host ubiquitin-conjugating enzyme, is a key regulator of hepatitis B virus maturation and egress.

The Journal of biological chemistry·2025

Same author

Synthetic host defense peptide inhibits SARS-CoV-2 replication <i>in vitro</i>.

Antimicrobial agents and chemotherapy·2025

Same author

Synthesis of 3'-modified xylofuranosyl nucleosides bearing 5'-silyl or -butyryl groups and their antiviral effect against RNA viruses.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Current tests to evaluate HIV-1 coreceptor tropism.

Justine D Rose¹, Ariel M Rhea, Jan Weber

¹Diagnostic HYBRIDS Inc, Cleveland, OH 44103, USA.

Current Opinion in HIV and AIDS

|April 3, 2009

Summary

This summary is machine-generated.

Accurate determination of HIV-1 coreceptor usage is crucial for managing patients on entry inhibitors. New methods are needed to detect CXCR4-tropic variants for effective HIV treatment.

More Related Videos

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 24, 2026

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

Virology
Immunology
Pharmacology

Background:

HIV-1 entry relies on envelope glycoproteins, CD4, and coreceptors CCR5/CXCR4.
Coreceptor identification spurred development of CCR5/CXCR4 antagonists for HIV treatment.
Understanding coreceptor usage is key for managing HIV-infected individuals.

Purpose of the Study:

Review methodologies for determining HIV-1 coreceptor usage.
Discuss the role of coreceptor tropism in managing patients on entry inhibitors.
Highlight the need for improved diagnostic tools.

Main Methods:

Review of existing phenotypic (cell-based) tropism assays.
Discussion of emerging genotypic (bioinformatic) tools.
Emphasis on sensitivity for detecting minor CXCR4-tropic variants.

Main Results:

Commercially available assays are primarily cell-based (phenotypic).
Development of bioinformatic (genotypic) tools is ongoing to improve speed and accuracy.
Detecting minor CXCR4-tropic variants in vivo remains a challenge.

Conclusions:

Accurate determination and quantification of HIV-1 coreceptor usage are essential for effective management with entry inhibitors.
Further research into novel methodologies is critical for the success of this drug class.
Improved tropism assays will enhance patient outcomes in the era of HIV entry inhibitors.